{
    "clinical_study": {
        "@rank": "6488", 
        "arm_group": {
            "arm_group_label": "MK-7145", 
            "arm_group_type": "Experimental", 
            "description": "MK-7145 2 mg IR administered as a single oral dose."
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to obtain a preliminary pharmacokinetic profile of\n      MK-7145 2 mg immediate release (IR) following single-dose administration in male\n      participants with moderate renal insufficiency. In addition, the study will evaluate the\n      pharmacodynamic effect of a single dose of MK-7145 2 mg IR on 24-hour net natriuresis in\n      male participants with moderate renal insufficiency."
        }, 
        "brief_title": "The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Insufficiency", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) 18 to 35 kg/m^2\n\n          -  Nonsmoker and/or have not used nicotine or nicotine-containing products\n\n        for at least 3 months prior to enrollment\n\n          -  Estimated glomerular filtration rate (eGFR) 30 to 60 mL/min/1.73 m^2\n\n        Exclusion Criteria:\n\n          -  History of stroke, chronic seizures, or major neurological disorder\n\n          -  Ongoing, clinically significant endocrine, gastrointestinal, cardiovascular,\n\n        hematological, hepatic, immunological, respiratory, or genitourinary abnormalities or\n        diseases\n\n          -  Systolic blood pressure (SBP) \u226495 mmHg or >160 mmHg, or diastolic blood\n\n        pressure (DBP) \u226445 mmHg or >95 mmHg\n\n          -  History of neoplastic disease except for adequately treated non-melanomatous skin\n             carcinoma\n\n          -  Unable to refrain from, or anticipates the use of, strong/moderate cytochrome P450\n             3A4 (CYP3A4) inhibitors\n\n          -  Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic\n             beverages, wine, or distilled spirits per day\n\n          -  Consumes excessive amounts of caffeine, defined as greater than 6 servings of coffee,\n             tea, cola, or other caffeinated beverages per day\n\n          -  Had major surgery or donated blood within 8 weeks prior to enrollment\n\n          -  Has participated in another investigational study within 4 weeks prior\n\n          -  History of significant multiple and/or severe allergies (including latex allergy), or\n             has had an anaphylactic reaction or significant intolerance to prescription or\n             nonprescription drugs or food\n\n          -  Currently a regular user of illicit drugs, or has a history of drug (including\n             alcohol) abuse within approximately 6 months\n\n          -  Has active or has a history of nephrolithiasis\n\n          -  Has had a kidney removed or has a functioning renal transplant"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832103", 
            "org_study_id": "7145-018", 
            "secondary_id": "2013-000838-35"
        }, 
        "intervention": {
            "arm_group_label": "MK-7145", 
            "intervention_name": "MK-7145", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 23, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study to Evaluate the Pharmacokinetics of MK-7145 Following Single Dose Administration in Patients With Moderate Renal Insufficiency", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Moldova: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Plasma-Time Curve From 0 to Infinity (AUC0-\u221e) of MK-7145 2 mg IR Following Single Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 Hours Post Dose"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of MK-7145 2 mg IR Following Single Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 Hours Post Dose"
            }, 
            {
                "measure": "Time to Maximum Plasma Concentration (Tmax) of MK-7145 2 mg IR Following Single Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 Hours Post Dose"
            }, 
            {
                "measure": "Apparent Half-Life (t 1/2) of MK-7145 2 mg IR Following Single Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 Hours Post Dose"
            }, 
            {
                "measure": "Oral Clearance (CL/F) of MK-7145 2 mg IR Following Single Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 Hours Post Dose"
            }, 
            {
                "measure": "Oral Volume of Distribution (V/F) of MK-7145 2 mg IR Following Single Dose Administration", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 Hours Post Dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832103"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change From Baseline in 24-Hr Urine Natriuresis (UNa0-24)", 
            "safety_issue": "No", 
            "time_frame": "24 Hours Prior to Dosing (Baseline) and Up to 24 Hours Post Dose"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}